Vaxcyte, Inc. (PCVX)
Automate Your Wheel Strategy on PCVX
With Tiblio's Option Bot, you can configure your own wheel strategy including PCVX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PCVX
- Rev/Share 0.0
- Book/Share 23.5832
- PB 1.4163
- Debt/Equity 0.0273
- CurrentRatio 17.6973
- ROIC -0.1934
- MktCap 4308733567.0
- FreeCF/Share -4.4219
- PFCF -7.1811
- PE -8.893
- Debt/Assets 0.0258
- DivYield 0
- ROE -0.1712
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PCVX | Cantor Fitzgerald | -- | Overweight | -- | -- | April 22, 2025 |
| Initiation | PCVX | Goldman | -- | Buy | -- | $135 | Dec. 20, 2024 |
News
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors.
Read More
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Negative
The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.
Read More
Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Andrew Guggenhime - President and CFO Grant Pickering - CEO Jim Wassil - EVP and COO Conference Call Participants Roger Song - Jefferies Salim Syed - Mizuho Umer Raffat - Evercore Seamus Fernandez - Guggenheim Tom Shrader - BTIG Joseph Stringer - Needham & Company Operator Good afternoon, my name is Jess, and I will be your conference operator today. At this time, I would like to welcome everyone to the Vaxcyte Fourth Quarter and Full Year 2024 Financial Results Conference Call.
Read More
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series of VAX-24 Infant Phase 2 Study by the End of First Quarter, Followed by Topline Data from Booster Dose by the End of 2025 --
Read More
About Vaxcyte, Inc. (PCVX)
- IPO Date 2020-06-12
- Website https://vaxcyte.com
- Industry Biotechnology
- CEO Mr. Grant E. Pickering M.B.A.
- Employees 414